Indian pharmaceutical company Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Daily Current Affairs Quiz 2020
Key-Points
Glenmark Pharmaceuticals has received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, according to the company’s statement.
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option.
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. The company initially sold its products in India, Russia, and Africa.
